Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Decanoates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 649 records · Page 36Linked to original sources
PubMed1980

[The course of long-term care with fluphenazine decanoate (Dapotum D)].

After 10 years experience with Dapotum D the statistically elaborated studies of catamnesis deal with 76 patients with more than 5 years permanent adjustment. The objective and subjective tolerance is compared (1) with patients with continuous ambulatory adjustment up to now; (2) patients with continuous in-patient adjustments, and (3) patients who withdrew Dapotum D or changed the medicaments after 5 or more years of permanent adjustment. The study shows a significant stabilization of the clinical picture and a surprisingly good permanent compatibility. This compatibility explains itself by the reduction of objective side effects in comparison with the phase of adjustment; the simultaneous habituation to slight extrapyramidal phenomena effects a very high degree of subjective contentment (90% of the patients). This may be supported by the fact that complete withdrawal of such permanent medication causes, in 36.9% of the patients, late dyskinesias with a tendency to slow remission; the latency of which binds doctor and patient, as indicated, to the successful therapy.

Fluphenazine↗
PubMedDate not supplied

[Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].

In the study the usefulness was assessed of haloperidol depot preparation in 50 mg ampoules produced by Warsaw Pharmaceutical Works POLFA in the treatment of schizophrenia. The study group comprised 30 patients, 12 females and 18 males, aged 18-70 years. Before haloperidol administration all other drugs were withdrawn. Haloperidol depot was injected intramuscularly after 7-10 days of oral administration of haloperidol. The injections were done at 3-week intervals during 26 weeks. The mean interval between the injections was 17.8 days, and the mean dose was 77.0 mg. The effectiveness of the drug was assessed using Overall scale (BPRS) measuring the intensity of 18 psychotic symptoms in the following weeks of the trial: 0, 1, 2, 3, 4, 7, 10, 13, 17, 20, 23 and 26. The depot haloperidol preparation (Decaldol) was studied assessing its effects on productive and defect symptoms and depression. The strongest effect was exerted on productive symptoms, less pronounced effect was on psychotic defects, and lowest on depression symptoms. Improvement of the psychosis was noted in 20 cases, deterioration in 8 and no change was observed in two patients. The present trial period was not completed by 19 patients, 6 due to psychotic deterioration, 5 patients had intense extrapyramidal adverse effects and in 2 cases worsening of mental condition was associated with adverse effects. In this subgroup of 19 patients 9 were improved, 8 were worse, and 2 had no change in relation to initial status. In the remaining 11 cases who completed the study only full of considerable improvement was found.

Adolescent↗